Business Context and Reporting Period
Company: Chimera Investment Corporation (CIM)
Filing Type: Form 8-K (Current Report)
Date of Report: June 8, 2020 (Event Date)
Reporting Period: Specific event reporting; not a periodic financial report.
Key Financial Metrics and Transaction Details
This filing details a new financing arrangement rather than periodic operating results. Key metrics include:
- Debt Facility: Entered into a $400 million senior secured, non-mark-to-market Credit Agreement.
- Collateral: Pledged approximately $550 million of existing assets (including ~$482 million in securities from mortgage loan securitizations).
- Interest Rate: 7% annual rate on term loans, with a potential increase of up to 3% upon certain events of default.
- Maturity Date: June 8, 2023.
- Equity Issuance: Issued warrants to purchase up to 20,300,000 shares of common stock (approx. 7.7% of post-issuance common stock).
- Warrant Terms: Exercise price of $0.10 per share; exercisable generally on the earlier of June 8, 2023, full discharge of the credit agreement, or an event of default.
Material Changes and Use of Proceeds
The primary material change is the establishment of the new $400 million credit facility funded on June 10, 2020. The net funds, after paying off related financing facilities, are designated for:
- Financing the acquisition of mortgage assets.
- Purchasing residential mortgage loans and mortgage-backed securities within targeted asset classes.
Outlook, Risks, and Unusual Items
Management Commentary: The company intends to use the facility to expand its portfolio of mortgage assets. The company may pledge additional assets to maintain the borrowed amount or substitute assets subject to conditions.
Risks and Contingencies:
- Default Risk: Interest rates may increase by up to 3% if certain events of default occur.
- Dilution: The issuance of warrants represents approximately 7.7% of the company's common stock, potentially diluting existing shareholders upon exercise.
- Pre-emptive Rights: Lenders were granted pre-emptive rights regarding future offerings of common stock.
- Settlement: The company may settle warrant exercises in cash at 90% of the fair market value of the stock at the time of exercise.
Unusual Items: The filing notes that the warrants were issued in a private placement and have not been registered under the Securities Act of 1933, relying on Section 4(a)(2) exemption.
Investor Verification Checklist
- Verify the specific assets pledged as collateral against the $400 million loan.
- Confirm the exact number of shares outstanding to calculate the precise dilution impact of the 20,300,000 warrant shares.
- Review the specific "events of default" that could trigger the 3% interest rate increase.
- Assess the impact of the pre-emptive rights granted to lenders on future capital raising activities.
- Check the status of the "related financing facilities" being paid off with the net proceeds.